Literature DB >> 21410391

Unintended consequences--the cost of preventing preterm births after FDA approval of a branded version of 17OHP.

Joanne Armstrong1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21410391     DOI： 10.1056/NEJMp1102796

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  5 in total

1.  Regulators place spotlight on drug prices.

Authors:  John Carroll
Journal:  Biotechnol Healthc       Date:  2011

2.  Innovation flourishes at a time of benefit coverage uncertainty.

Authors:  F Randy Vogenberg
Journal:  Biotechnol Healthc       Date:  2012

3.  Hydroxyprogesterone caproate injection (makena) one year later: to compound or not to compound that is the question.

Authors:  Yesha Patel; Martha M Rumore
Journal:  P T       Date:  2012-07

4.  Utilization, Cost, and Outcome of Branded vs Compounded 17-Alpha Hydroxyprogesterone Caproate in Prevention of Preterm Birth.

Authors:  Inbar Fried; Andrew L Beam; Isaac S Kohane; Nathan P Palmer
Journal:  JAMA Intern Med       Date:  2017-11-01       Impact factor: 21.873

Review 5.  Use of progesterone supplement therapy for prevention of preterm birth: review of literatures.

Authors:  Suk-Joo Choi
Journal:  Obstet Gynecol Sci       Date:  2017-09-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.